Physician profile
John Roveda
NPI 1477014264
$712.91
in general payments reported to CMS, 2019-2025
16 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.62 · 2024: $267 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $103.56 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Novocure INC. | $91.04 | 2024-2025 | Optune Gio, Optune |
| Novartis Pharmaceuticals Corporation | $87.61 | 2025 | |
| Janssen Biotech, INC. | $82.87 | 2024-2025 | Darzalex, Tecvayli, Balversa |
| Genzyme Corporation | $49.78 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $37.70 | 2025 | Libtayo |
| Eisai INC. | $36.65 | 2024-2025 | |
| Incyte Corporation | $35.54 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Emd Serono, INC. | $33.82 | 2025 | |
| Tersera Therapeutics LLC | $31.30 | 2024 | Quzyttir |
| Pfizer INC. | $29.41 | 2024 | |
| Genentech USA, INC. | $21.80 | 2024 | Tecentriq |
| Argenx US, INC. | $20.02 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $19.53 | 2025 | Jaypirca, Verzenio |
| Sumitomo Pharma America, INC. | $18.66 | 2025 | Orgovyx |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roveda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.